After propensity score matching against multiple antidiabetic drug classes (insulin, metformin, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas), results showed: No significant increase in thyroid cancer incidence Median follow-up of ~4.5 years Risk estimates comparable or lower than other glucose-lowering therapies Overall, current epidemiological evidence does not support a clinically meaningful increase in thyroid cancer risk in humans
Liposomal iron is not just another anemia supplement
Individual Variation: Baseline pigmentation darkness, genetics, and sun damage history affect timeline
and some of their featured characteristics.
Sriram, K., & Manzanares, W
Many patients describe feeling younger overallnot surprising given that the therapy restores growth hormone patterns closer to those of youth